Dr. Sarah Chen is Chief Scientific Officer at AntibodyLLM, where she leads the company's AI-driven antibody design research and scientific strategy. She joined AntibodyLLM at its founding in 2020 and has been instrumental in developing the platform's large language model-based sequence design engine and its proprietary CHO cell expression system.
Her expertise spans computational protein engineering, structural biology, CHO cell biomanufacturing, and the application of machine learning to antibody discovery and optimization. She has directed multiple projects achieving industry-leading results, including antibody expression yields of 3.2 g/L and picomolar binding affinities for novel oncology targets.
Areas of Expertise
- AI / LLM applications in antibody and protein design
- Computational sequence-structure-function modeling
- CHO cell stable expression systems (CRISPR, UCOE)
- Bispecific antibody engineering
- Recombinant protein production and process development
- Antibody affinity maturation and humanization
Articles by Dr. Sarah Chen
The Future of AI-Driven Antibody Design
How large language models and generative AI are transforming antibody discovery — from sequence-structure modeling to multi-objective optimization.
CRISPR Site-Specific Integration for Stable CHO Cell Lines
How CRISPR eliminates random insertion variability in CHO cells, enabling consistent high-yield antibody expression stable for 50+ generations.
UCOE Technology: Eliminating Gene Silencing in Stable Cell Lines
Ubiquitous Chromatin Opening Elements prevent epigenetic silencing, ensuring long-term stable antibody expression without methylation-driven gene inactivation.
How AI Reduces Antibody Development Costs by 50%
AntibodyLLM's AI-first approach predicts expression and affinity before wet-lab work — cutting costs and timelines by 50%.
Bispecific Antibodies: Challenges and Advances
Bispecific antibodies offer dual-targeting power but face chain pairing, low yields, and purification complexity. How AntibodyLLM's AI platform solves these bottlenecks.
Why CHO Cells Remain the Gold Standard for Antibody Manufacturing
CHO cells produce 70%+ of approved biologics. Discover the biology behind their dominance and how AntibodyLLM's proprietary CHO platform pushes yields beyond 3 g/L.